Dexcom Inc Stock Price, News & Analysis

Dexcom (NASDAQ: DXCM) has announced the fourth season of Dexcom U, its unique Name, Image and Likeness (NIL) program for college athletes with diabetes. The program is launching its first nationwide search for new athletes to join its 2025 roster, with nominations open through May 23.

Selected athletes will join eight returning members at the Dexcom U Signing Day Camp this summer, hosted by Baltimore Ravens tight end Mark Andrews. Participants will receive access to Dexcom Continuous Glucose Monitoring (CGM) technology, exclusive events, and networking opportunities with collegiate and professional athletes.

The program aims to showcase athletes who manage diabetes while competing at high levels, using Dexcom G7 technology to monitor their glucose levels in real-time through smartphones and smartwatches. The selection committee will focus on candidates who can serve as role models and share inspiring stories with the next generation of youth athletes.

Dexcom (NASDAQ:DXCM) has received FDA clearance for its Dexcom G7 15 Day Continuous Glucose Monitoring System for people over 18 with diabetes in the United States. The new system boasts an impressive 15.5 days of wear time and superior accuracy with an overall MARD of 8.0%.

Key features include waterproof capability, direct Apple Watch connectivity, automated activity logging, and a 12-hour grace period for sensor replacement. The system also offers remote glucose sharing with caregivers and enhanced alert settings.

The company plans to launch Dexcom G7 15 Day in the second half of 2025 and is working with insulin pump partners to ensure compatibility with automated insulin delivery systems. Clinical data presented at the Advanced Technologies and Treatments for Diabetes conference in Amsterdam confirms G7 15 Day as the most accurate CGM for adults.

DexCom (NASDAQ:DXCM) has announced its upcoming first quarter 2025 earnings release and conference call schedule. The company will disclose its Q1 2025 financial results after market close on Thursday, May 1, 2025.

Management will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the quarterly performance. Investors can access the call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID '9430114'. A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.

Dexcom (NASDAQ: DXCM) announces expanded public coverage for its continuous glucose monitoring (CGM) systems in Saskatchewan, Canada. The government's new coverage now includes young adults aged 18-25 and seniors over 65 who use any type of insulin, adding to existing coverage for ages 2-18.

The expansion, part of Budget 2025, will benefit nearly 10,000 individuals living with diabetes in the province. Dexcom's G7 and G6 CGM systems feature a predictive Urgent Low Soon alert that warns users up to 20 minutes before severe hypoglycemic events, helping prevent dangerous blood sugar levels below 3.1 mmol/L.

The systems integrate with various insulin pumps and digital health apps, including the Dexcom Follow app for remote monitoring by family members. This coverage expansion represents a significant advancement in diabetes care accessibility in Saskatchewan.

Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, has appointed Jon Coleman as Chief Commercial Officer. Coleman brings over 30 years of global commercial leadership experience and will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.

Coleman previously served as an executive officer at Masimo (NASDAQ: MASI) for 15 years, where he was president of commercial teams. He managed worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service. Prior to Masimo, Coleman held leadership positions at Pfizer (NYSE: PFE) Consumer Healthcare, including vice president and general manager of Canada and the Caribbean region, with additional experience in Asia and Latin America.

Throughout his career, Coleman has demonstrated success in scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

Dexcom (NASDAQ: DXCM) unveiled groundbreaking developments at ATTD 2025, including first-ever data for its G7 15 Day system showing an impressive 8.0% MARD, making it the most accurate CGM sensor available. The company also released a multi-region report surveying over 2,500 people across Europe and the Middle East.

Key findings from the report reveal that 52% of healthcare professionals favor CGM technology and education over medication for Type 2 diabetes management. The study showed 93% of CGM users reported positive impact, significantly exceeding pre-use expectations of 77%. Additionally, 96% of HCPs agreed CGM should be standard care for multiple daily insulin injection users.

Dexcom strengthened its position as the most connected CGM brand by announcing new integrations with Omnipod® 5 Automated Insulin Delivery System in multiple regions and direct connectivity with NovoPen® 6 and NovoPen Echo® Plus in Germany, with planned expansion to other markets.

DexCom (NASDAQ:DXCM), the global leader in glucose biosensing, has appointed Renée Galá to its Board of Directors, effective March 6, 2025. Galá currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals, a global biopharmaceutical company with over $4 billion in 2024 revenues.

In her role at Jazz Pharmaceuticals, Galá oversees global business operations including commercial operations, research and development, manufacturing, corporate strategy and quality. She brings significant financial, strategic, and operational leadership experience across the life sciences sector, including expertise in international expansion initiatives and business development collaborations.

Dexcom (NASDAQ:DXCM) has announced its upcoming participation in the 46th Annual Raymond James Institutional Investors Conference. The company's management will deliver a corporate update presentation on Tuesday, March 4th at 10:25 AM EST.

The presentation will be available through a concurrent webcast, accessible via the Dexcom Investor Relations website at investors.dexcom.com. For those unable to attend live, the presentation will be archived on the website for future viewing.

DexCom (DXCM) reported its Q4 and fiscal year 2024 results, with Q4 revenue growing 8% year-over-year to $1.114 billion. U.S. revenue increased 4% while international revenue grew 17%. Full-year revenue reached $4.033 billion, up 11% from 2023.

Q4 GAAP operating income was $188.9 million (17.0% of revenue), showing a 400 basis points decrease compared to Q4 2023. Net income was $151.7 million, or $0.38 per diluted share. The company maintained a strong cash position of $2.58 billion.

Strategic highlights include the FDA submission of Dexcom G7 15-day CGM system, secured reimbursement for Dexcom ONE+ in France, and a partnership with ŌURA. For 2025, Dexcom projects revenue of $4.60 billion (14% growth) with a Non-GAAP Operating Margin of approximately 21%.